Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,851.50    31.00 (1.70%)
Bid:
1,851.50
Ask:
1,852.00
Spread: 0.50 (0.027%)
Market Cap: £74.25b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

24 Feb 2026 15:30

RNS Number : 2045U
GSK PLC
24 February 2026
 

GSK plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Hal Barron

b)

Position/status

Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

 

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of notional ADS within Dr Barron's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$59.5200

2,007.552

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-02-20

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

James Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

 

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of notional ADS within Mr Ford's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$59.5200

47.460

d)

Aggregated information

N/A (single transaction)

 

Aggregated volume Price

e)

Date of the transaction

2026-02-20

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSEAFFLEMSEEE
Date   Source Headline
1st Jun 20263:00 pmRNSTotal Voting Rights
1st Jun 20263:00 pmRNSTransaction in Own Shares
28th May 20269:30 amRNSPositive Phase 3 data for bepirovirsen
27th May 20263:30 pmRNSDirector/PDMR Shareholding
26th May 20263:00 pmRNSAdmission to Trading
26th May 20263:00 pmRNSTransaction in Own Shares
22nd May 202610:30 amRNSQ2 2026 Results Date Confirmed - 28 July 2026
20th May 20263:30 pmRNSDirector/PDMR Shareholding
19th May 20263:30 pmRNSDirector/PDMR Shareholding
18th May 20263:00 pmRNSTransaction in Own Shares
18th May 20267:00 amRNSJapan MHLW approves Arexvy for adults 18-49 AIR
14th May 20263:30 pmRNSDirector/PDMR Shareholding
11th May 20263:30 pmRNSDirector/PDMR Shareholding
11th May 20267:05 amRNSCollaboration with CTTQ for bepirovirsen
11th May 20267:00 amRNSGSK - final tranche of share buyback programme
6th May 20266:22 pmRNSResult of AGM
5th May 20263:30 pmRNSDirector/PDMR Shareholding
1st May 20263:00 pmRNSHolding(s) in Company
1st May 20263:00 pmRNSTotal Voting Rights
29th Apr 20263:30 pmRNSDirector/PDMR Shareholding
29th Apr 20267:00 amRNS1st Quarter Results
28th Apr 20263:30 pmRNSDirector/PDMR Shareholding
28th Apr 20267:00 amRNSBepirovirsen priority review US filing acceptance
27th Apr 202612:00 pmRNSEfimosfermin granted US/EU regulatory designations
27th Apr 20267:00 amRNSTESARO update on AnaptysBio Inc. litigation
24th Apr 20263:30 pmRNSDirector/PDMR Shareholding
23rd Apr 20267:00 amRNSTransaction in Own Shares
22nd Apr 20267:00 amRNSTransaction in Own Shares
21st Apr 20267:00 amRNSTransaction in Own Shares
20th Apr 20263:30 pmRNSDirector/PDMR Shareholding
20th Apr 20267:00 amRNSBlenrep approved in China for 2L+ multiple myeloma
20th Apr 20267:00 amRNSTransaction in Own Shares
17th Apr 20267:00 amRNSTransaction in Own Shares
16th Apr 20263:30 pmRNSDirector/PDMR Shareholding
16th Apr 20267:00 amRNSTransaction in Own Shares
15th Apr 20267:12 amRNSGSK completes acquisition of 35Pharma Inc.
15th Apr 20267:00 amRNSTransaction in Own Shares
14th Apr 20263:30 pmRNSDirector/PDMR Shareholding
14th Apr 20267:00 amRNSTransaction in Own Shares
13th Apr 20263:30 pmRNSDirector/PDMR Shareholding
13th Apr 20267:00 amRNSTransaction in Own Shares
13th Apr 20267:00 amRNSGSK presents positive data for BEHOLD 1 B7 H4 ADC
10th Apr 20263:30 pmRNSDirector/PDMR Shareholding
10th Apr 20267:00 amRNSTransaction in Own Shares
9th Apr 20263:30 pmRNSDirector/PDMR Shareholding
9th Apr 20267:00 amRNSTransaction in Own Shares
8th Apr 20267:00 amRNSExdensur approved for CRSwNP in China
8th Apr 20267:00 amRNSTransaction in Own Shares
7th Apr 20267:00 amRNSTransaction in Own Shares
2nd Apr 20267:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.